Amicus Therapeutics Inc (LTS:0HF9)
$ 10.0592 0.0812 (0.81%) Market Cap: 2.98 Bil Enterprise Value: 3.17 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 11, 2023 / 03:40PM GMT
Release Date Price: $11.09
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Okay, everybody. Good morning. Thanks for joining us here in Las Vegas at the Bank of America Healthcare Conference. I'm Tazeen Ahmad, I'm one of the senior biotech analysts here. It's my pleasure to have with me on stage. Amicus Therapeutics speaking for Amicus for the next half hour is, of course, President and CEO, Brad Campbell. Brad, thanks for making the trip out here.

Bradley L. Campbell
Amicus Therapeutics, Inc. - CEO, President & Director

Thank you for having us, Tazeen. Thanks to Bank of America for hosting good-to-see people.

Questions & Answers

Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

And so I think this is a timely conversation for us to have. You did share some good news, the long-awaited inspection of your Wuxi facility in preparation for final approval for Pompe, so maybe talk to us about, obviously, what went into that inspection and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot